Status:
COMPLETED
Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease
Lead Sponsor:
R.S. Djamin
Collaborating Sponsors:
Erasmus Medical Center
Stichting Solong
Conditions:
COPD
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To assess whether maintenance treatment with macrolide antibiotics in COPD patients with three or more exacerbations in the preceding year of inclusion can decrease the exacerbation rate in the year o...
Detailed Description
COPD is characterized by progressive development of airflow limitation that is poorly reversible. Because of a poor understanding of COPD pathogenesis, treatment is mostly symptomatic and new therapeu...
Eligibility Criteria
Inclusion
- Diagnosis of COPD according to GOLD criteria (FEV1/FVC\<70%), classification into GOLD I (FEV1 70-100% predicted), GOLD II (FEV1 50-70% predicted), GOLD III (FEV1 30- 50% predicted) or GOLD IV (FEV1 ≤ 30% predicted)
- Age ≥ 18 years
- Three or more exacerbations of COPD in one year for which a course of prednisone and/or antibiotic therapy was started
- Clinically stable during 1 month. Patients have to be free of COPD exacerbation or respiratory tract infection within a month prior to involvement in the study and they should not have received a high dose of systemic glucocorticoids or antibiotics in this period
- Informed consent
Exclusion
- Use of antibiotics or high dose of systemic steroids within a month prior to involvement in the study.
- Addition of inhalation steroids to the patient's therapy regimen, shortly before entering the study.
- Pregnant or lactating women.
- Allergy to macrolides.
- Liver disease (alanine transaminase and/or aspartate transaminase levels 2 or more times the upper limit of normal).
- Asthma, defined as episodic symptoms of airflow obstruction which is reversible with bronchodilators, assessed with lung function testing.
- Presence of a malignancy which is clinically active.
- Bronchiectasis.
- Malignancy of any kind for which the subject is under treatment or is being monitored as part of follow up after treatment.
- Heart failure.
- Use of drugs which can adversely interact with macrolides and for which therapeutic monitoring cannot be undertaken.
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT00985244
Start Date
May 1 2010
End Date
June 1 2013
Last Update
June 26 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Amphia Ziekenhuis
Breda, North Brabant, Netherlands, 4818 CK